Tiziana Life Sciences to Spin Out IL-6 Asset into Separate Public Company
I'm PortAI, I can summarize articles.
Tiziana Life Sciences Ltd. plans to spin out its anti-IL-6 receptor monoclonal antibody, TZLS-501, into a separate public company to enhance strategic focus and unlock shareholder value. Shareholders will receive shares in the new entity, pending approval and listing requirements. This follows increased interest in IL-6 therapeutics, highlighted by Novartis' $1.4 billion acquisition of Tourmaline Bio.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments